Gain Therapeutics Inc has a consensus price target of $8.17, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co. on April 25, 2024, April 23, 2024, and April 1, 2024. With an average price target of $9 between HC Wainwright & Co., Oppenheimer, and HC Wainwright & Co., there's an implied 195.08% upside for Gain Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/25/2024 | GANX | Buy Now | Gain Therapeutics | $3.05 | 195.08% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
04/23/2024 | GANX | Buy Now | Gain Therapeutics | $3.05 | 195.08% | Oppenheimer | Hartaj Singh | → $9 | Maintains | Outperform | Get Alert |
04/01/2024 | GANX | Buy Now | Gain Therapeutics | $3.05 | 195.08% | HC Wainwright & Co. | Raghuram Selvaraju | → $9 | Reiterates | Buy → Buy | Get Alert |
03/27/2024 | GANX | Buy Now | Gain Therapeutics | $3.05 | 96.72% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
12/04/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 195.08% | HC Wainwright & Co. | Raghuram Selvaraju | $10 → $9 | Maintains | Buy | Get Alert |
09/18/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | Maxim Group | Jason McCarthy | → $10 | Initiates | → Buy | Get Alert |
08/31/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
08/14/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 96.72% | Chardan Capital | Keay Nakae | → $6 | Reiterates | Buy → Buy | Get Alert |
08/14/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
06/12/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | Oppenheimer | Hartaj Singh | → $10 | Reiterates | Outperform → Outperform | Get Alert |
05/15/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
05/15/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 96.72% | Chardan Capital | Keay Nakae | $5.75 → $6 | Maintains | Buy | Get Alert |
05/01/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | → Buy | Get Alert |
03/27/2023 | GANX | Buy Now | Gain Therapeutics | $3.05 | 88.52% | Chardan Capital | Keay Nakae | $4 → $5.75 | Maintains | Buy | Get Alert |
12/09/2022 | GANX | Buy Now | Gain Therapeutics | $3.05 | 31.15% | Chardan Capital | Keay Nakae | → $4 | Initiates | → Buy | Get Alert |
11/25/2022 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | Oppenheimer | Hartaj Singh | $30 → $10 | Maintains | Outperform | Get Alert |
11/14/2022 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | HC Wainwright & Co. | Raghuram Selvaraju | $12 → $10 | Maintains | Buy | Get Alert |
11/14/2022 | GANX | Buy Now | Gain Therapeutics | $3.05 | 227.87% | BTIG | Thomas Shrader | $30 → $10 | Maintains | Buy | Get Alert |
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on April 25, 2024. The analyst firm set a price target for $9.00 expecting GANX to rise to within 12 months (a possible 195.08% upside). 14 analyst firms have reported ratings in the last year.
The latest analyst rating for Gain Therapeutics (NASDAQ: GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.
There is no last upgrade for Gain Therapeutics.
The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on April 25, 2024 so you should expect the next rating to be made available sometime around April 25, 2025.
While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $0.00 to $9.00. The current price Gain Therapeutics (GANX) is trading at is $3.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.